2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid, often abbreviated as **DTPA-NCS**, is a chelating agent with a unique structure designed for attaching to proteins, peptides, or other molecules. Here's a breakdown of its structure and importance in research:
**Structure:**
* **Diethylenetriaminepentaacetic acid (DTPA):** This is the core structure of the molecule. It's a powerful chelator, meaning it can bind to metal ions like gadolinium (Gd) or technetium (Tc).
* **6-methyl:** This modification provides a slightly altered structure compared to standard DTPA, potentially impacting its binding properties and reactivity.
* **2-(4-isothiocyanatobenzyl):** This is the key functional group for conjugation. The isothiocyanate (-NCS) moiety is highly reactive and can form a stable covalent bond with amines (NH2) found in proteins.
**Importance in Research:**
DTPA-NCS is a valuable tool for researchers due to its ability to:
* **Label proteins and peptides:** It allows the attachment of a metal ion (e.g., Gd or Tc) to a protein. This allows researchers to track the protein's location in cells or tissues using techniques like magnetic resonance imaging (MRI) or single-photon emission computed tomography (SPECT).
* **Develop targeted drug delivery systems:** DTPA-NCS can be used to attach therapeutic drugs to specific antibodies or proteins, enabling targeted drug delivery. This is crucial for treating diseases like cancer where specific cells need to be targeted.
* **Study protein-protein interactions:** By attaching a fluorescent molecule or a reporter group via DTPA-NCS, researchers can track the interactions between proteins and understand their biological functions.
* **Develop new diagnostic tools:** DTPA-NCS can be used to create new contrast agents for medical imaging, enhancing the visualization of specific tissues or organs.
**Specific Applications:**
* **Cancer research:** DTPA-NCS is used to develop targeted therapies for various cancers by attaching drugs or radioisotopes to antibodies that specifically bind to cancer cells.
* **Neuroimaging:** DTPA-NCS is used to label proteins involved in neurological processes, enabling researchers to study brain function and potential disease mechanisms.
* **Immunology:** DTPA-NCS helps label antibodies for studying immune responses and developing new immunotherapies.
**Summary:**
DTPA-NCS is a versatile tool for researchers in various fields. Its ability to bind to metal ions and attach to proteins makes it essential for developing new imaging agents, targeted therapies, and tools for studying complex biological processes.
2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid: a bifunctional chelating agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 3036099 |
MeSH ID | M0207599 |
Synonym |
---|
141849-44-7 |
2-(p-scn-bz)-6-methyl-dtpa |
acetamide, n-(2-(diacetylamino)-3-(4-isocyanatophenyl)propyl)-n-(2-(diacetylamino)propyl)- |
2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid |
n-[2-(diacetylamino)-3-(4-isothiocyanatophenyl)propyl]-n-[2-(diacetylamino)propyl]acetamide |
n-acetyl-n-(1-{acetyl[2-(diacetylamino)-3-(4-isothiocyanatophenyl)propyl]amino}propan-2-yl)acetamide |
DTXSID90931213 |
Excerpt | Reference | Relevance |
---|---|---|
" Because of observations in therapeutic trials of yttrium-90 (90Y) escape from radioimmunoconjugates and uptake by the skeleton with resultant bone marrow toxicity, the authors attempted to evaluate the importance of this factor by a comparison of the LD50 in healthy mice treated with 90Y that had been chelated with either of two high affinity chelators, methylbenzyldiethylene-triaminepentaacetic acid (MX-DTPA) or bromoacetamidobenzyl-1,4,7,10-tetraazocyclododecane- N,N',N'',N'''-tetraacetic acid (BAD)." | ( Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). DeNardo, GL; DeNardo, SJ; Fand, I; Kroger, LA; Kukis, DL; Meares, CF; Miers, LA; Renn, O; Salako, Q; Shen, S, 1994) | 0.29 |
" The LD50 for 90Y-BrE-3-MX-DTPA was 220." | ( Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). DeNardo, GL; DeNardo, SJ; Fand, I; Kroger, LA; Kukis, DL; Meares, CF; Miers, LA; Renn, O; Salako, Q; Shen, S, 1994) | 0.29 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 12 (66.67) | 18.2507 |
2000's | 4 (22.22) | 29.6817 |
2010's | 2 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.88) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (13.64%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (86.36%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |